Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Pyxis Oncology Inc (PYXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: PYXS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.23
1 Year Target Price $6.23
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 493.48% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 243.45M USD | Price to earnings Ratio - | 1Y Target Price 6.23 |
Price to earnings Ratio - | 1Y Target Price 6.23 | ||
Volume (30-day avg) 7 | Beta 1.33 | 52 Weeks Range 0.83 - 5.39 | Updated Date 11/6/2025 |
52 Weeks Range 0.83 - 5.39 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.58 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -676.1% |
Management Effectiveness
Return on Assets (TTM) -31.25% | Return on Equity (TTM) -74.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 70058803 | Price to Sales(TTM) 86.33 |
Enterprise Value 70058803 | Price to Sales(TTM) 86.33 | ||
Enterprise Value to Revenue 24.84 | Enterprise Value to EBITDA 1.09 | Shares Outstanding 62264215 | Shares Floating 40884835 |
Shares Outstanding 62264215 | Shares Floating 40884835 | ||
Percent Insiders 23.39 | Percent Institutions 34.9 |
Upturn AI SWOT
Pyxis Oncology Inc
Company Overview
History and Background
Pyxis Oncology, Inc. is a clinical-stage oncology company focused on developing next-generation antibody-drug conjugates (ADCs) and immunotherapies to target difficult-to-treat cancers. Founded in 2019 and headquartered in Cambridge, Massachusetts, the company went public in October 2020 (initial Public Offering).
Core Business Areas
- ADC Development: Developing antibody-drug conjugates (ADCs) targeting solid tumors.
- Immunotherapy Development: Developing immunotherapies including innate immunotherapies.
Leadership and Structure
Lara S. Sullivan, M.D., serves as the President and Chief Executive Officer. The company has a management team overseeing research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- PYX-106: An anti-Siglec-15 antibody designed to modulate the tumor microenvironment. Currently in Phase 1 clinical trials. Competitors include companies developing similar immune-oncology therapies, e.g. antibodies targeting Siglec-15. Revenue is currently $0.
- PYX-201: An ADC targeting Fibroblast Activation Protein (FAP). Currently in Phase 1 clinical trials. Competitors include other ADC developers targeting FAP, such as those from Roche and Boehringer Ingelheim. Revenue is currently $0.
Market Dynamics
Industry Overview
The oncology therapeutics market is highly competitive and rapidly evolving, with significant investment in novel therapies such as ADCs and immunotherapies. The market is driven by increasing cancer incidence and prevalence and is expected to grow significantly in the coming years.
Positioning
Pyxis Oncology is positioned as a developer of next-generation cancer therapies, focusing on ADCs and immunotherapies for difficult-to-treat cancers. The company's pipeline aims to address unmet needs in specific tumor types.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars annually. Pyxis Oncology's TAM depends on the specific indications their pipeline addresses, but it could be a multi-billion-dollar opportunity if their therapies are successful.
Upturn SWOT Analysis
Strengths
- Novel ADC and immunotherapy pipeline
- Experienced management team
- Focus on difficult-to-treat cancers
- Collaboration with key academic institutions
Weaknesses
- Early-stage pipeline with high clinical development risk
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes
- No products currently generating revenue
Opportunities
- Potential for breakthrough therapies in unmet medical needs
- Partnerships and collaborations with larger pharmaceutical companies
- Expansion of pipeline into new cancer targets
- Positive clinical trial data leading to increased investor interest
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- SNY
- MRK
- BMY
Competitive Landscape
Pyxis Oncology competes with established pharmaceutical companies and other biotech firms developing cancer therapies. Pyxis Oncology's competitive advantage lies in its novel ADC and immunotherapy approaches targeting difficult-to-treat cancers.
Growth Trajectory and Initiatives
Historical Growth: Pyxis Oncology's growth has been primarily driven by the advancement of its clinical pipeline and successful fundraising efforts.
Future Projections: Future growth depends on the successful completion of clinical trials and potential commercialization of its drug candidates. Analyst estimates will vary based on clinical results and market conditions.
Recent Initiatives: Recent initiatives include progressing PYX-106 and PYX-201 through Phase 1 clinical trials and establishing collaborations to support pipeline development.
Summary
Pyxis Oncology is a clinical-stage company with a promising pipeline of ADC and immunotherapy candidates, which are in Phase 1. The company has a strong focus on novel cancer targets. However, it faces significant risks associated with clinical development and relies heavily on funding. Successful clinical trial outcomes and securing partnerships are crucial for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Company Website
- Investor presentations
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. The data and analysis presented are based on available information and are subject to change without notice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pyxis Oncology Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-10-08 | CEO, President, Chief Medical Officer & Director Dr. Lara S. Sullivan M.D., MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 44 | Website https://www.pyxisoncology.com |
Full time employees 44 | Website https://www.pyxisoncology.com | ||
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.